Actithera is dedicated to developing precisely targeted radioligand therapies to serve cancer patients with high unmet medical needs.
VISION STATEMENT
Actithera leverages proprietary chemistries to design best-in-class radioligand therapies that persist in tumors while sparing healthy tissues. We are driven by a collaborative and empowering culture where talented individuals come together with a shared mission: to transform the lives of cancer patients through innovative science.
Science overview
Actithera is built on a proprietary chemistry platform designed to maximize tumor absorbed radiation dose while minimizing off-target exposure. Our approach is isotope-agnostic, enabling flexible pairing of radionuclides based on biological rationale and tumor characteristics. This versatility allows us to target a broad range of cancer indications with precision and purpose.
Origin story
Founded in 2021 by Andreas Goutopoulos, Actithera was born from a deep expertise in small molecule oral drug design and a bold vision: to bring that same precision and rigor to the discovery of life-changing radioligand therapies.
